Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation. - Wikidata - wikimedia - TriplyDB

Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.

Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.

http://www.wikidata.org/entity/Q37358630

about

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses to Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Cystic Fibrosis.Pharmacokinetics and Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers.Use of ceftolozane-tazobactam in a cystic fibrosis patient with multidrug-resistant pseudomonas infection and renal insufficiency.Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. Cephalosporins and penicillins update.Time-Kill Analysis of Ceftolozane/Tazobactam Efficacy Against Mucoid Pseudomonas aeruginosa Strains from Cystic Fibrosis Patients.Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa.Effects of Clinically Meaningful Concentrations of Antipseudomonal β-Lactams on Time to Detection and Organism Growth in Blood Culture Bottles.

P2860

Q38636242-191DBE08-203C-46F5-A7ED-5C41B79D18A9 Q40052714-FC86D617-36FF-4890-9C3B-6B1835120D62 Q47165438-E0E36E0E-1EB8-48B4-8B7F-F893004A5777 Q48313437-7BAAEB5C-17DC-4BA9-B715-9AB63BE4E400 Q49445381-CB926EE6-E314-433E-BB59-AB9154965FAA Q49616791-D53CE4D8-F975-431B-85C0-94487E366325 Q50095636-829635C0-59B7-4721-88A4-915026BB00CA

P2860

Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.

http://www.wikidata.org/entity/Q37358630

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 22 August 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Population Pharmacokinetics an ...... Acute Pulmonary Exacerbation.

@en

Population Pharmacokinetics an ...... Acute Pulmonary Exacerbation.

@nl

type

label

Population Pharmacokinetics an ...... Acute Pulmonary Exacerbation.

@en

Population Pharmacokinetics an ...... Acute Pulmonary Exacerbation.

@nl

prefLabel

Population Pharmacokinetics an ...... Acute Pulmonary Exacerbation.

@en

Population Pharmacokinetics an ...... Acute Pulmonary Exacerbation.

@nl

P1433

Q37358630-066283AD-8678-480D-A278-70A7E9DECBA8

P1476

Q37358630-60407D6A-2F1A-4F4A-B25F-36689CAE45B2

P2093

Q37358630-527A1919-8ABA-44E5-8633-CD63AEB4753C

Q37358630-5FE5BF01-AF6B-4B3E-B6D1-A3BD64491F52

Q37358630-79D0D3ED-0C6F-499A-94A9-E7E21E22B5F4

Q37358630-869A46B2-DF93-4F48-BD5F-6E620D117036

Q37358630-D482087D-7CDB-4A46-84D2-0648DC933D7E

Q37358630-E8719685-DEBD-4EB1-BCEC-596F61C1D299

P2860

Q37358630-08DA09BF-1CF3-4D71-8CB3-CAD81FDECC05

Q37358630-1C8441E7-4276-4BEB-9017-E53F1A0DE202

Q37358630-21891A47-4ACA-470A-BA41-21CCD34F375F

Q37358630-2B2A9F61-38C2-41EC-941D-A77DD3C85552

Q37358630-40A5EE9F-A8B9-4A1B-9897-8651BB6AA95F

Q37358630-451EF4E9-9052-496E-9D8C-1B3D3AE2C5D6

Q37358630-4B933CDF-DDB6-4E86-8E62-33450EFFC4E1

Q37358630-531929EE-EE15-4939-8711-1872549C311E

Q37358630-5BC719C1-CBBE-4E7C-A217-4A9AFCB1A631

Q37358630-60C65E9F-B8BC-4A9F-89A3-F4F81FB88DBA

P304

Q37358630-E6FE5779-0568-49AF-9D3F-326CF6BACC64

P31

Q37358630-1D6B6173-2DE2-4ACA-AE9E-C6E236A29229

P356

Q37358630-44E2092D-35A1-45BE-A08C-B41D7929F94C

P407

Q37358630-822EEA76-E020-46AA-B6A3-93BD9D8F8D6D

P433

Q37358630-C5E1CF71-6444-4ABA-B49F-B78BA797CF6F

P478

Q37358630-F796A7AE-CE7E-4CF3-B6CF-21EAF71ED538

P577

Q37358630-70C17F0C-BD34-48F7-872C-826CBC877375

P698

Q37358630-11F5A2B4-8730-4AD6-8E58-40708BDF5966

P921

Q37358630-36CB5A77-9B54-4814-B1A8-CC0511CFF157

P932

Q37358630-BE1F5853-8EFD-4934-AC00-C9C45B6FC164

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Population Pharmacokinetics an ...... Acute Pulmonary Exacerbation.

@en

P2093

David P Nicolau

http://www.w3.org/2001/XMLSchema#string

Jeffrey J Cies

http://www.w3.org/2001/XMLSchema#string

Joseph L Kuti

http://www.w3.org/2001/XMLSchema#string

Marguerite L Monogue

http://www.w3.org/2001/XMLSchema#string

Marianne Muhlebach

http://www.w3.org/2001/XMLSchema#string

Rebecca S Pettit

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa.

Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions.

Effects of obesity on pharmacokinetics implications for drug therapy.

Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.

Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.

In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa

Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections.

Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses.

Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R

Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities.

P304

6578-6584

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01566-16

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27550351

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis

P932

5075062

http://www.w3.org/2001/XMLSchema#string